Exogenous DNA Stabilizes cfRNA via Triplex Structures
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for analyzing cell-free RNA (cfRNA) in biological fluids face challenges such as low abundance, instability, and interference from DNA in downstream assays, limiting their sensitivity and specificity for cancer diagnosis and monitoring.
Innovation Solution
The introduction of exogenous DNA and/or DNAse inhibitors into biological fluids to stabilize and increase the yield of cfRNA, allowing for the formation of protective triplex structures that resist degradation, and the use of RNAse inhibitors to maintain RNA integrity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If exogenous DNA is added to stabilize RNA, then RNA stability and yield are improved, but DNA contamination in downstream assays worsens
Solution Approach 1:
The patent introduces an intermediary substance (exogenous DNA) that mediates the stabilization of RNA through formation of protective triplex structures. This intermediary binds to RNA and prevents degradation, thereby improving RNA stability without requiring removal of the stabilizing agent itself.
Solution Approach 2:
The patent converts the potentially harmful effect of DNA contamination into a beneficial stabilization mechanism. By adding exogenous DNA, the patent creates triplex structures that protect RNA from degradation, turning what would normally be considered contamination into a protective element.
2Stability of the object's composition
If DNAse inhibitors are used to prevent DNA degradation, then DNA integrity is improved, but RNA stability worsens due to interference with downstream assays
Solution Approach 1:
The patent uses an intermediary approach by introducing exogenous DNA that serves as a mediator for RNA stabilization. This exogenous DNA forms triplex structures with RNA, protecting it from degradation while the DNAse inhibitor ensures the exogenous DNA remains intact to continue providing stabilization.
3Stability of the object's composition
If RNA is processed immediately to prevent degradation, then RNA stability is improved, but analysis time is reduced
Solution Approach 1:
The patent applies preliminary action by adding exogenous DNA and DNAse inhibitors to the sample at the time of collection. This preliminary stabilization allows the RNA to remain stable during transport and storage, eliminating the need for immediate processing while maintaining RNA integrity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly stabilizes and increases the yield of cfRNA, enabling more sensitive and specific analysis for disease diagnosis and monitoring, even in low-abundance samples, without interfering with downstream assays.
Implementation Method 1
The introduction of exogenous DNA and/or DNAse inhibitors into biological fluids to stabilize and increase the yield of cfRNA, allowing for the formation of protective triplex structures that resist degradation
Implementation Method 2
The introduction of exogenous DNA and/or DNAse inhibitors into biological fluids to stabilize and increase the yield of cfRNA
Implementation Method 3
the use of RNAse inhibitors to maintain RNA integrity
Data Source
AI summary
RNA from a biological fluid is stabilized during isolation and/or storage using DNA. In especially preferred aspects, the RNA is cfRNA and/or ctRNA, and the biological fluid is blood.